<html>

<head>


   <meta http-equiv="Content-Language" content="en-us">
   <meta name="GENERATOR" content="Microsoft FrontPage 5.0">
   <meta name="ProgId" content="FrontPage.Editor.Document">
   <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
   <title>ADVANCED LIPID TESTING</title>
   <style>
      p.MsoNormal {
         mso-style-parent: "";
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText {
         margin-bottom: .0001pt;
         line-height: 150%;
         font-size: 14.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText2 {
         margin-bottom: .0001pt;
         text-align: justify;
         line-height: 150%;
         layout-grid-mode: char;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.Index {
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }
   </style>
</head>

<body>

   <p class="MsoNormal" align="center"><b><u>
            <span style="font-family: Arial;">
               <font size="4">ADVANCED LIPID TESTING</font>
            </span></u></b></p>
   <p class="MsoNormal" style="text-align: left;" align="center"><b><u>
            <span style="font-family: Arial;">
               <font size="4">Topic Highlights</font>
            </span></u></b></p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
      <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
         <font size="4">&nbsp;&nbsp; Cardiovascular risk factors extend beyond cholesterol to include small proteins and
            lipoprotein subtypes.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
      <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial;">
         <font size="4">Cardiovascular risk is better assessed by identifying measurable lipid risk factors using newer
            techniques.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
      <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial;">
         <font size="4">The kinds of lipids and their functions, the risk factors associated with abnormal lipid levels,
            the advanced lipid testing methods, and the role of these methods in clinical assessment are discussed in
            detail in this presentation.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="line-height: 150%;" align="left">&nbsp;</p>
   <p class="MsoNormal" style="line-height: 150%;" align="center">
      <b><u><span style="line-height: 150%; font-family: Arial;">
               <font size="4">
                  Transcript</font>
            </span></u></b>
   </p>
   <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
         <span style="line-height: 150%; font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%;" align="left">
      <span style="line-height: 150%; font-family: Arial;">
         <font size="4">
            <a href="https://en.m.wikipedia.org/wiki/Lipid" style="color: blue; text-decoration: underline;">
               Lipid</a>-related cardiovascular <a href="https://en.m.wikipedia.org/wiki/Risk_factors"
               style="color: blue; text-decoration: underline;">risk factors</a> include not only <a
               href="https://en.m.wikipedia.org/wiki/Cholesterol"
               style="color: blue; text-decoration: underline;">cholesterol</a> but also <a
               href="https://en.m.wikipedia.org/wiki/Lipoproteins"
               style="color: blue; text-decoration: underline;">lipoproteins</a>
            and their subtypes. Cardiovascular risk is best assessed by identifying measurable lipid risk factors.
            Advanced lipid testing, therefore, plays a crucial role in clinical practice. This presentation discusses in
            detail the kinds of lipids and their functions, the risk factors associated with abnormal levels of lipids,
            and the role of advanced lipid testing in clinical assessment.
         </font>
      </span>
   </p>
   <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
         <span style="line-height: 150%; font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%;" align="left">
      <span style="line-height: 150%; font-family: Arial;">
         <font size="4"> <a href="https://en.m.wikipedia.org/wiki/Atherosclerosis"
               style="color: blue; text-decoration: underline;">Atherosclerotic</a> <a
               href="https://en.m.wikipedia.org/wiki/Cardiovascular_disease"
               style="color: blue; text-decoration: underline;">cardiovascular disease</a> (CVD) is a major cause of
            mortality and morbidity. Its main acute clinical manifestations are <a
               href="https://en.m.wikipedia.org/wiki/Myocardial_infarction"
               style="color: blue; text-decoration: underline;">myocardial infarction</a> and <a
               href="https://en.m.wikipedia.org/wiki/Stroke" style="color: blue; text-decoration: underline;">stroke</a>.
            The treatment of risk factors is the most important, urgent, and effective way to prevent these diseases.
            Various forms of <a href="https://en.m.wikipedia.org/wiki/Dyslipidemia"
               style="color: blue; text-decoration: underline;"><i>dyslipidemia</i></a> (disorders of <a
               href="https://en.m.wikipedia.org/wiki/Blood_lipids" style="color: blue; text-decoration: underline;">blood
               lipids</a>) are important causative risk factors for atherosclerotic CVD. Other significant risk factors
            that are easily determined in clinical practice are smoking, overweight/<a
               href="https://en.m.wikipedia.org/wiki/Obesity"
               style="color: blue; text-decoration: underline;">obesity</a>, <a
               href="https://en.m.wikipedia.org/wiki/Hypertension"
               style="color: blue; text-decoration: underline;">hypertension</a>, and <a
               href="https://en.m.wikipedia.org/wiki/Diabetes"
               style="color: blue; text-decoration: underline;">diabetes</a>.
         </font>
      </span>
   </p>
   <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
         <span style="line-height: 150%; font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%;" align="left">
      <span style="line-height: 150%; font-family: Arial;">
         <font size="4">
            Lipid testing is used here in the context of 'determination of lipids in blood for the evaluation of a
            person's cardiovascular risk status.' Lipid testing began early in the 20th century when the <a
               href="https://en.m.wikipedia.org/wiki/Lieberman%E2%80%93Burchard_test"
               style="color: blue; text-decoration: underline;">Lieberman'Burchard reaction</a> for cholesterol was
            devised, making it possible to determine the concentration of plasma cholesterol, which soon led to the
            discovery that plasma cholesterol is often high in patients with myocardial infarction. In the mid-1960s,
            the prospective <a href="https://en.m.wikipedia.org/wiki/Framingham_Heart_Study"
               style="color: blue; text-decoration: underline;">Framingham study</a> demonstrated that cholesterol is a
            risk factor for the development of <a href="https://en.m.wikipedia.org/wiki/Coronary_disease"
               style="color: blue; text-decoration: underline;">coronary heart disease</a> (CHD). Soon after,
            researchers realized that cholesterol and other lipids in the blood are bound to <a
               href="https://en.m.wikipedia.org/wiki/Proteins"
               style="color: blue; text-decoration: underline;">proteins</a> called <a
               href="https://en.m.wikipedia.org/wiki/Apolipoproteins"
               style="color: blue; text-decoration: underline;">apolipoproteins</a> (apo) and are part of large
            complexes called lipoproteins.
         </font>
      </span>
   </p>
   <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
         <span style="line-height: 150%; font-family: Arial;">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%;" align="left">
      <span style="line-height: 150%; font-family: Arial;">
         <font size="4">
            <b>Classification of Lipoproteins</b><br>
            Using <a href="https://en.m.wikipedia.org/wiki/Micro-encapsulation#Physico-chemical_methods"
               style="color: blue; text-decoration: underline;">physicochemical methods</a>, plasma lipoproteins have
            been classified into three major groups:<br><br>
            <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
               <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                  style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                  <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Very_low-density_lipoprotein"
                        style="color: blue; text-decoration: underline;">very low density lipoprotein</a> (VLDL),
                     estimated from <a href="https://en.m.wikipedia.org/wiki/Triglyceride"
                        style="color: blue; text-decoration: underline;">triglyceride</a> values </font>
               </span>
            </p>
            <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
               <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                  style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                  <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Low-density_lipoprotein"
                        style="color: blue; text-decoration: underline;">low-density lipoprotein</a> (LDL), measured as
                     LDL cholesterol (LDL-C)</font>
               </span>
            </p>
            <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
               <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                  style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                  <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/High-density_lipoprotein"
                        style="color: blue; text-decoration: underline;">high-density lipoprotein</a> (HDL), measured as
                     HDL cholesterol (HDL-C)</font>
               </span>
            </p>
            <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                  <span style="line-height: 150%; font-family: Arial;">
                     <font size="4">&nbsp;</font>
                  </span></b></p>
            <p class="MsoNormal" style="line-height: 150%;" align="left">
               <span style="line-height: 150%; font-family: Arial;">
                  <font size="4">
                     Of these groups, LDL carries a major part of plasma cholesterol and is the most atherogenic
                     lipoprotein class; hence, LDL-C is called 'the bad cholesterol.' In contrast, HDL-C protects
                     against <a href="https://en.m.wikipedia.org/wiki/Atherosclerosis"
                        style="color: blue; text-decoration: underline;">atherosclerosis</a> and is hence called 'the
                     good cholesterol.' Therefore, both high levels of LDL-C and low levels of HDL-C are risk factors
                     for CHD.
                  </font>
               </span>
            </p>
            <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                  <span style="line-height: 150%; font-family: Arial;">
                     <font size="4">&nbsp;</font>
                  </span></b></p>
            <p class="MsoNormal" style="line-height: 150%;" align="left">
               <span style="line-height: 150%; font-family: Arial;">
                  <font size="4">
                     <b>Lipid Profile</b><br>
                     Presently, most laboratories provide clinicians with the following <a
                        href="https://en.m.wikipedia.org/wiki/Lipid_profile"
                        style="color: blue; text-decoration: underline;">lipid profile</a>:<br><br>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;total cholesterol </font>
                        </span>
                     </p>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;triglycerides </font>
                        </span>
                     </p>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;LDL-C </font>
                        </span>
                     </p>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;HDL-C </font>
                        </span>
                     </p>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;non-HDL-C </font>
                        </span>
                     </p>
                     <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;" align="left">
                        <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                           style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                           <font size="4">&nbsp;&nbsp;ratios of LDL-C to HDL-C or LDL-C to total <br>
                              <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                    <span style="line-height: 150%; font-family: Arial;">
                                       <font size="4">&nbsp;</font>
                                    </span></b></p>
                              <p class="MsoNormal" style="line-height: 150%;" align="left">
                                 <span style="line-height: 150%; font-family: Arial;">
                                    <font size="4">
                                       In addition to this standard lipid profile, many laboratories also determine the
                                       major apo components of LDL, VLDL, and HDL:<br><br>
                                       <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                          align="left">
                                          <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                                             style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                             <font size="4">&nbsp;&nbsp;<a
                                                   href="https://en.m.wikipedia.org/wiki/Apolipoprotein_B"
                                                   style="color: blue; text-decoration: underline;">apo B</a> </font>
                                          </span>
                                       </p>
                                       <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                          align="left">
                                          <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                                             style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                             <font size="4">&nbsp;&nbsp;<a
                                                   href="https://en.m.wikipedia.org/wiki/Apolipoprotein_A1"
                                                   style="color: blue; text-decoration: underline;">apo A-I</a></font>
                                          </span>
                                       </p>
                                       <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                          align="left">
                                          <font size="4"><span style="font-family: Arial;"></span></font>&#9679;<span
                                             style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                             <font size="4">&nbsp;&nbsp;ratios of LDL-C to HDL-C or LDL-C to total
                                             </font>
                                          </span>
                                       </p><br>
                                       <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                             <span style="line-height: 150%; font-family: Arial;">
                                                <font size="4">&nbsp;</font>
                                             </span></b></p>
                                       <p class="MsoNormal" style="line-height: 150%;" align="left">
                                          <span style="line-height: 150%; font-family: Arial;">
                                             <font size="4">
                                                Apo B reflects the amount of LDL plus VLDL, and apo A-I indicates the
                                                amount of HDL. There is presently an ongoing discussion if the apo's and
                                                their ratios are better predictors of CHD than the lipid profile.<br>
                                                Advanced lipid testing measures the following:<br><br>
                                                <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                                   align="left">
                                                   <font size="4"><span style="font-family: Arial;"></span></font>
                                                   &#9679;<span
                                                      style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                                      <font size="4">&nbsp;&nbsp;cholesterol content of the subclasses
                                                         of the major lipoprotein classes </font>
                                                   </span>
                                                </p>
                                                <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                                   align="left">
                                                   <font size="4"><span style="font-family: Arial;"></span></font>
                                                   &#9679;<span
                                                      style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                                      <font size="4">&nbsp;&nbsp;size and number of lipoprotein
                                                         particles in the various subclasses </font>
                                                   </span>
                                                </p>
                                                <p class="MsoNormal" style="text-indent: -0.25in; margin-left: 0.5in;"
                                                   align="left">
                                                   <font size="4"><span style="font-family: Arial;"></span></font>
                                                   &#9679;<span
                                                      style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial;">
                                                      <font size="4">&nbsp;&nbsp;other lipoprotein species such as <a
                                                            href="https://en.m.wikipedia.org/wiki/Lp%28a%29"
                                                            style="color: blue; text-decoration: underline;">Lp(a)</a>
                                                      </font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">
                                                         Both LDL and HDL are heterogeneous lipoprotein classes
                                                         consisting of lipoprotein particles varying in size,
                                                         composition, and atherogenicity.<br><br>
                                                         Small and dense LDL (sdLDL) particles, an LDL subclass, are
                                                         more atherogenic than the larger, more buoyant LDL particles
                                                         because they are smaller (penetrate easier into the <a
                                                            href="https://en.m.wikipedia.org/wiki/Artery"
                                                            style="color: blue; text-decoration: underline;">arterial
                                                            wall</a>), more prone to modification by oxidation, and
                                                         therefore more rapidly taken up by the <a
                                                            href="https://en.m.wikipedia.org/wiki/Scavenger_receptor"
                                                            style="color: blue; text-decoration: underline;">scavenger
                                                            receptors</a> of the <a
                                                            href="https://en.m.wikipedia.org/wiki/Macrophage"
                                                            style="color: blue; text-decoration: underline;">macrophages</a>,
                                                         which then turn into <a
                                                            href="https://en.m.wikipedia.org/wiki/Foam_cell"
                                                            style="color: blue; text-decoration: underline;">foam
                                                            cells</a>, a characteristic feature of atherosclerotic <a
                                                            href="https://en.m.wikipedia.org/wiki/Lesion"
                                                            style="color: blue; text-decoration: underline;">lesions</a>.
                                                         sdLDL is now recognized as a strong risk factor for CHD both in
                                                         Western and Japanese populations. This observation is becoming
                                                         more and more evident that it is important to pay attention not
                                                         only to LDL-C, but also to sdLDL and its significance in the
                                                         evaluation of a patient's risk for CHD and in the prevention of
                                                         CHD.
                                                      </font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">The protective HDL is also a heterogeneous
                                                         lipoprotein class, the subclasses of which have been ascribed
                                                         different atheroprotective potentials. Attention is directed
                                                         toward the larger HDL, particularly the large HDL2 subclass,
                                                         which appears to be the most protective HDL subclass. HDL2 is
                                                         actively engaged in <a
                                                            href="https://en.m.wikipedia.org/wiki/Reverse_cholesterol_transport"
                                                            style="color: blue; text-decoration: underline;">reverse
                                                            cholesterol transport</a>, the process by which cholesterol
                                                         can be transported away from atherosclerotic lesions to the
                                                         liver for excretion from the body via the bile. Lp(a) is a
                                                         distinct genetic form of LDL that contains apo(a) in addition
                                                         to apo B. Apo(a) has a structural similarity to <a
                                                            href="https://en.m.wikipedia.org/wiki/Plasminogen"
                                                            style="color: blue; text-decoration: underline;">plasminogen</a>
                                                         . Lp(a) is a strong risk factor for clinical atherosclerosis.
                                                         Unlike LDL, Lp(a) does not respond to treatment with diet or <a
                                                            href="https://en.m.wikipedia.org/wiki/Statins"
                                                            style="color: blue; text-decoration: underline;">statins</a>.
                                                         However, its concentration is markedly reduced by <a
                                                            href="https://en.m.wikipedia.org/wiki/Nicotinic_acid"
                                                            style="color: blue; text-decoration: underline;">nicotinic
                                                            acid</a>.
                                                      </font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">Several methods are available for the determination
                                                         of lipoprotein subclasses, and these methods are still mostly
                                                         used in research or clinical trials. However, with the
                                                         increasing awareness of the importance of various subclasses in
                                                         the <a
                                                            href="https://en.m.wikipedia.org/wiki/Reverse_cholesterol_transport"
                                                            style="color: blue; text-decoration: underline;">reverse
                                                            cholesterol transport</a> of atherosclerosis and as risk
                                                         factors for CVD, these methods will undoubtedly be used more
                                                         frequently in clinical practice. This development will be in
                                                         response to clinicians' demands to obtain more advanced lipid
                                                         profiles in which lipoprotein subclasses are also determined.
                                                         Since the groundbreaking work of <a
                                                            href="https://en.m.wikipedia.org/wiki/John_Gofman"
                                                            style="color: blue; text-decoration: underline;">John
                                                            Gofman</a> with <a
                                                            href="https://en.m.wikipedia.org/wiki/Analytical_ultracentrifugation#Analytical_ultracentrifuge"
                                                            style="color: blue; text-decoration: underline;">analytical
                                                            ultracentrifugation</a> in the 1990s, human plasma
                                                         lipoproteins have been well established as a very heterogeneous
                                                         group of proteins or particles, greatly varying in size,
                                                         density, and composition. The different characteristics of the
                                                         subclasses have made it possible to separate and quantify these
                                                         proteins or particles by physicochemical methods, such as <a
                                                            href="https://en.m.wikipedia.org/wiki/Electrophoresis"
                                                            style="color: blue; text-decoration: underline;">electrophoresis</a>
                                                         and ultracentrifugation.</font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">
                                                         <a href="https://en.m.wikipedia.org/wiki/Polyacrylamide"
                                                            style="color: blue; text-decoration: underline;">Polyacrylamide</a>
                                                         gradient <a
                                                            href="https://en.m.wikipedia.org/wiki/Gel_electrophoresis">gel
                                                            electrophoresis</a> has been used for 25 years as a
                                                         practical method for the separation and analysis of
                                                         lipoproteins of different sizes, such as HDL and LDL particles
                                                         that vary in diameter (7'12 nm and 21'28 nm, respectively). <a
                                                            href="https://en.m.wikipedia.org/wiki/Polyacrylamide_gel">Polyacrylamide
                                                            gels</a> have pores of decreasing size in the direction of
                                                         the electrophoretic mobility, preventing lipoproteins of a
                                                         certain size from moving further on in the gel in the electric
                                                         field.<br><br>
                                                         To analyze HDL subfractions, a gradient in the range of 4%'30%
                                                         polyacrylamide concentration is used. With this technique, HDL
                                                         is separated into five distinct subclasses.
                                                      </font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">To determine LDL subclasses, 2%'16% polyacrylamide
                                                         gel is generally applied. Gradient gel electrophoresis of LDL
                                                         has identified seven subclasses. There is, however, no standard
                                                         nomenclature for these subclasses. At present, the most useful
                                                         terms for LDL subclasses are the two <a
                                                            href="https://en.m.wikipedia.org/wiki/Phenotypes">phenotypes</a>
                                                         of LDL described by Austin. Phenotype A contains large LDL,
                                                         while phenotype B consists of sdLDL. The determination of sdLDL
                                                         is the most significant measurement of LDL subclasses for the
                                                         evaluation of a person's risk for CHD.</font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">In ultracentrifugation, the density of lipoproteins
                                                         is due to their lipid content; that is, the lipid/protein ratio
                                                         determines the separation and identification of the various
                                                         subclasses. Analytical ultracentrifugation is the standard for
                                                         a quantification of lipoprotein classes, but it is too
                                                         laborious and expensive for routine use. The recently developed
                                                         SVAP method is a single vertical spin <a
                                                            href="https://en.m.wikipedia.org/wiki/Density_gradient#Biology">density
                                                            gradient ultracentrifugation</a> combined with cholesterol
                                                         analysis of the separated lipoprotein classes. The advantages
                                                         of SVAP are the use of small plasma samples, short
                                                         centrifugation time, and determination of an advanced
                                                         quantitative lipoprotein subclass spectrum.</font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">The determination of plasma lipoprotein subclasses
                                                         by <a
                                                            href="https://en.m.wikipedia.org/wiki/NMR_spectroscopy">nuclear
                                                            magnetic resonance (NMR) spectroscopy</a> started in the
                                                         1990s. A plasma sample is placed in the NMR analyzer, and a
                                                         spectrum is recorded within a minute. By computer analysis of
                                                         the spectrum, the amounts of large, medium, and small particle
                                                         subclasses of VLDL, LDL, and HDL are estimated.</font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">Studies of the subclasses of both LDL and HDL have
                                                         revealed important clinical and metabolic differences between
                                                         the subclasses. Several prospective <a
                                                            href="https://en.m.wikipedia.org/wiki/Epidemiology">epidemiological
                                                            studies</a> have shown that sdLDL is a very important risk
                                                         factor for the development of atherosclerotic CVD. According to
                                                         some studies, sdLDL is an even better indicator of CHD risk
                                                         than LDL-C. For example, in a prospective Quebec study
                                                         comprising more than 2000 men free of CHD, the subjects with
                                                         high levels of sdLDL but normal concentrations of LDL-C had a
                                                         fourfold increased risk for new events of CVD. High levels of
                                                         sdLDL are common in <a
                                                            href="https://en.m.wikipedia.org/wiki/Hypertriglyceridemia">hypertriglyceridemia</a>,
                                                         which is often present in <a
                                                            href="https://en.m.wikipedia.org/wiki/Type_2_diabetes">type 2
                                                            diabetes</a> and <a
                                                            href="https://en.m.wikipedia.org/wiki/Metabolic_syndrome">metabolic
                                                            syndrome</a>. The concentration of sdLDL can be reduced by
                                                         lifestyle improvements and by <a
                                                            href="https://en.m.wikipedia.org/wiki/Pharmacology">pharmacological
                                                            treatment</a> with statins, nicotinic acid, and <a
                                                            href="https://en.m.wikipedia.org/wiki/Fibrate">fibrates</a>.
                                                      </font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">Both progression and severity of coronary
                                                         atherosclerosis are inversely proportional to the large HDL2b
                                                         subclass, which appears to have a more protective effect
                                                         against atherosclerosis than other HDL subclasses. There is a
                                                         pronounced difference in the distribution of HDL subclasses
                                                         between men and women. Particularly noteworthy is that men have
                                                         lower levels of protective HDL2, which partly explains the
                                                         higher incidence of CHD in males than in females at a younger
                                                         age. Fibrates and statins increase HDL-C by about 5%'20%, and
                                                         nicotinic acid increases HDL-C by 20%'40%. The pharmacological
                                                         treatment with statins, nicotinic acid, and fibrates also
                                                         decreases the HDL2 subclass by about 100% and the HDL3 subclass
                                                         by 20%, which further illustrates the importance of evaluating
                                                         the subclasses of the major lipoprotein classes by advanced
                                                         lipid testing.</font>
                                                   </span>
                                                </p><br>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left"><b>
                                                      <span style="line-height: 150%; font-family: Arial;">
                                                         <font size="4">&nbsp;</font>
                                                      </span></b></p>
                                                <p class="MsoNormal" style="line-height: 150%;" align="left">
                                                   <span style="line-height: 150%; font-family: Arial;">
                                                      <font size="4">Given the prevalence of CHD and CVD, tests to
                                                         obtain detailed profiles of lipid subclasses are a necessity.
                                                         Advanced lipid testing, though not recommended for routine
                                                         screening, is important in identifying individuals at high risk
                                                         of CHD or CVD, especially those with a family history of
                                                         premature CHD, individuals with an intermediate risk for CHD,
                                                         and <a
                                                            href="https://en.m.wikipedia.org/wiki/Postmenopausal#Postmenopause">postmenopausal</a>
                                                         women. These tests will facilitate early identification, more
                                                         effective treatments, and an overall reduction in the
                                                         occurrence of atherosclerotic CVD.</font>
                                                   </span>
                                                </p><br>

                                                <center>
                                                   <div id="google_translate_element"></div>
                                                </center>
                                                <script type="text/javascript">
                                                   function googleTranslateElementInit() {
                                                      new google.translate.TranslateElement({ pageLanguage: 'en' }, 'google_translate_element');
                                                   }
                                                </script>

                                                <script type="text/javascript"
                                                   src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script>


<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>